US police have confirmed that Brian Thompson was fatally shot outside an investor conference by a masked assailant.

An open-label Phase III trial showed that participants using Zepbound saw 47% greater relative weight loss compared to Wegovy.

Maze Therapeutics has completed a Series D financing round, raising $115m to propel the development of its lead candidates, MZE829 and MZE782.

Ipsen has entered an exclusive worldwide licensing agreement with Biomunex Pharmaceuticals to develop BMX-502.

Takeda has signed an agreement to receive an exclusive global licence from Keros Therapeutics for elritercept.